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Abstract.
The interaction of two antitumor ruthenium(Ill) complexes,-Na[trans-RuCI4(DMSO)(Im)] and
Na[trans-RuCI4(DMSO)(Ind)]- with human serum apotransferdn (apoTf) was investigated through
a number of spectroscopic techniques such as UV-Vis absorption, CD and 1H NMR
spectroscopy. Interestingly, the hydrolysis profiles of these complexes in a physiological buffer
are markedly affected by the presence, in solution, of apoTf suggesting the occurrence of a
specific interaction of their respective hydrolysis products with the protein. The formation of
stable adducts with apotransferdn has been demonstrated by CD spectroscopy, and additional
information obtained through 1H NMR of the hyperfine shifted signals. The bound ruthenium(Ill)
species may be detached from these adducts by addition of excess citrate at low pH. The
behavior of the investigated ruthenium(Ill) complexes with apoTf is compared with that of the
recently described and stdctly related ru-im and ru-ind antitumour complexes, and discussed in
the frame of general strategies of drug targeting.
Introduction.
After the discovery of the excellent antitumor properties of cisplatin, in the late seventies,
large interest has concentrated on the design and the synthesis of other platinum and non-
platinum metal complexes to be used for anticancer chemotherapyI The main goal of the
intense research activity conducted in this field is to prepare new inorganic compounds that are
active versus tumor cell lines ..not sensitive to cisplatin; moreover several attempts are being
done to increase the selectivity of these compounds for the target tissue and reduce their
systemic toxicity. So, a large number of platinum derivatives as well as several compounds with
other metals like ruthenium, titanium, tin, and gold, have been synthesized and tested for
anticancer properties1. In some cases these compounds demonstrated, in comparison to
cisplatin, a different pattern of in vitro antitumor activities and a lower systemic toxicity.
Unfortunately, only few compounds passed the first phases of the pharmacological evaluation
and are now in clinical trials. Complexes that are about entedng the first phase of clinical trials
are the ruthenium(Ill) complexes imidazolium trans(bisimidazole) tetrachlomruthenate(lll) (ru-im
or ICR) and indazolium trans(bisindazole) tetrachlomruthenate(lll) (ru-ind), developed by
Keppler, for which a good antitumor activity versus several human colon carcinoma cell lines has
been reported1"3. The corresponding ruthenium(Ill) compounds developed by the group of
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by a DMSO moiety (respectively Na[trans-RuCI4(DMSO)(Im)] (I) and Na[trans-
RuCI4(DMSO)(Ind)]) (11) seem promising3. In an effort to improve the antitumor properties of all
these ruthenium(Ill) compounds, we have undertaken an extensive research program aimed at
the preparation of conjugates with natural or artificial biomolecules capable to confer selectivity
towards the desired biological targets. We started from the consideration that these metal
complexes, like several other anticancer compounds, are relatively simple molecules with a
limited amount of chemical information and therefore scarce selectivity for the target; this is
probably one of the main masons of their low specificity and of the consequent high toxicity. We
thought that this problem could be overcome, at least in part, by adopting appropriate drug
targeting strategies, for instance by linking these drugs to biological macromolecules endowed
with high selectivity for well defined biological targets. Successful targeting strategies are,
indeed, those capable of attaining a high local concentration of the drug at the level of a certain
organ or tissue while keeping its concentration low in the other districts4"6.
Our drug targeting project stems on the utilization of transferrin as the carrier
biomolecule. The choice of transferrin is based on the following masons: i) transferrin is
physiologically present in the biological fluids and therefore virtually devoid of immuno=qenicity7;
ii) transferfin exhibits good binding properties for metal ions and metal complexes u; iii) the
protein enters cells easily through the transferdn cycle comprising protein recognition by a
specific cell surface receptor and internalization into an endosomic compartmentg; iv) the
expression rate of the transferdn receptors is markedly enhanced in fastproliferating cells so that
the uptake rate of the drug-protein adducts by the tumor cells is high10,11; v) the fact that the
protein, during its intracellular cycle, passes through an acidic compartment gives us the chance
of pr.epadng acid-labile adducts capable of releasing the drug inside the cell where the pH is
low 12.
Strategies of drug targeting using transferrin as carder were first reported dudng the
eighties by Faulk et al. who prepared and tested transferdn conjugates of doxorubicin.13"15 We
have resumed early Faulk’s ideas and attempted to apply them to these ruthenium(Ill)
complexes. In.a previous study we already investigated the interaction of ru-im and ru-ind with
apotransferrin16. We report here the analysis of the interaction of complexes and II with
apotransferrin. Interestingly, the latter complexes are far more soluble in water and therefore
easier to be handled with.
Materials and Methods
complexes and II were synthesized as previously described17. Human serum
apotransferrin was purchased from Sigma Chemical Company and further purified according to
standard procedures18. In all the experiments a physiological buffer was used so that the final
salt concentrations were always 0.004 M NaH2PO4, 0.1 M NaCI and 0.025 M NaHCO3 with pH
7.4.
The absorption spectra were recorded both on a Cary 17D and a Cary 3
spectrophotometer; the CD spectra on a JASCO 200C spectropolarimeter. The 1H NMRMetal-BasedDngs L. Messori, F. Kratz andhL Alessio
experiments were performed on a Bruker MSL 200 spectrometer operating at 4.7 T, typically
using 0.5 ml. samples in 5 mm tubes. In order to improve the detection of the broad hyperfine
shifted signals short relaxation delays of the order of 50-100 ms were used. Each spectrum
typically consisted of 32,000-64,000 scans. The FIDs of 8 K data points each, were processed
using line broadening factors of the order of 10-30 Hz.
Results
Hydrolysis of I and II within the physiological buffer: the electronic spectra.
Complexes and II are relatively stable under acidic conditions but rapidly hydmlyze at
neutral or alkaline pH. Hydrolysis can be easily followed by monitoring the absorption spectra in
dependence of time as already reported for complex 17. Under physiological conditions
hydrolysis appears to be at least a two-step process, the first step corresponding to the loss of a
first chloride group and the second step to further hydrolytic events. The spectra of and II,
recorded at increasing time intervals after mixing with the buffer, at 25C, are shown in Figure 1A
and 2A, respectively. The initial spectra are characterized by an intense band at 385 nm plus a
shoulder at 445 nm in the case of and by a band at 395 nm plus a shoulder at 465 nm in the
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Figure 1 Hydrolysis of in the physiological buffer in the absence (A) and in the presence
(B) of apoTf as followed through absorption spectroscopy. Traces a, b, c in Figure A were
respectively recorded 5, 30 and 180 minutes after mixing. Trace d is the spectrum recorded the
day after. Traces a, b, c in Figure B were recorded at 3, 10 and 30 minutes after mixing. Trace d
was recorded the day after. Conditions: [I] was 2x10-4 M; protein concentration lx10-4 M. A
physiological buffer containing 0.004 M NaH2PO4, 0.1 M NaCI and 0.025 M NaHCO3 was used,
with pH 7.4. T= 25C.P’ol. 3, No. 1o 1996 The Interaction ofthe Antitumor Complexes
case of II. Within few minutes the two main bands and the respective shoulders quickly decrease
in intensity and eventually vanish whereas a new intense band appears in both cases around 345
nm. The intensity of the new band reaches a maximum after about half an hour, then, on turn,
starts decreasing and vanishes. The final spectrum of in the buffer, recorded several hours
later, is characterized by a broad band in the UV with a shoulder around 320 nm. In the case of II,
a marked increase in the intensity of the whole spectrum is observed with time; a new, broad
band also develops around 570 nm.
Hydrolysis of I and II in the presence ofApoTf- the electronic spectra.
In order to ascertain whether complexes and II interact with apotransferrin we decided
to repeat the above hydrolysis experiments within the buffer in the presence of apoTfo The family
of spectra obtained upon hydrolysis of and II in the presence of the protein are respectively
shown in Figure 1B and 2B.
The first part of the hydrolysis of both complexes within the buffer as monitored through
absorption spectroscopy is not significantly affected by apoTf even if the hydrolysis rates are
significantly enhanced. During the second phase of the hydrolysis, however, the absorption
spectra, differ significantly from those obtained in the absence of apoTf. The final spectra are
invariably characterized by a broad, relatively intense transition in the visible, located around 500
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Figure 2 Hydrolysis of II in the buffer in the absence (A) and in the presence (B) of apoTf
as followed through absorption spectroscopy. Traces a, b, c and d in Figure A were respectively
recorded 3, 30 and 120 and 240 minutes after mixing. Trace e is the spectrum recorded the day
after. Traces a, b, c in Figure B were recorded at 3, 10 and 30 minutes after mixing. Trace d was
recorded the day after.Conditions: [11] was 2x10-4 M; protein concentration lx10-4 M. A
physiological buffer containing 0.004 M NaH2PO4, 0.1 M NaCI and 0.025 M NaHCO3 was used
with pH 7.4. T= 25C.L. Messori, F. Kratz andE. Alessio Metal-BasedDrugs
nm in the case of complex and around 540 nm in the case of complex II. These results indicate
that both complexes or, more precisely, their hydrolysis products do interact with apotransferrin
and that the interaction occurs in concomitance with the second hydrolytic process.
Interaction of I and II with apoTf- the CD spectra.
To better elucidate the formation of specific adducts between complexes and II and
apoTf we analyzed the final hydrolysis products obtained both in the absence and in the presence
of apoTf, by CD spectroscopy. CD spectroscopy is a valuable tool to demonstrate the specific
binding of small metal complexes, with transitions in the visible region, to chiral biomolecules19.
Whereas, as expected, no CD band was observed in the case of the complexes dissolved in the
buffer, the spectra of the samples dissolved in buffered apoTf solutions, at a 2:1 ratio, showed
characteristic CD transitions in the visible region (Figure 3). More in detail, the spectrum of plus
apoTf consists of two positive transitions at 370 and 480 nm; that of II plus apoTf shows two
positive transitions at 375 and 495 nm. The detection of these CD transitions provides
unambiguous evidence for a tight interaction between the ruthenium(Ill) chromophore and the
chiral macromolecule in both cases. Interestingly the CD spectra develop a few hours after
mixing in concomitance with the second hydrolytic process of both complexes.
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Figure 3 CD spectra in the visible region of plus-apoTf (A) and II plus-apoTf (B). At 25 C
both spectra fully develop about 60-90 minutes after mixing. The samples of Figures 1B and 2B
were used.
The CD spectra differ markedly from those, previously reported, of ruthenium(Ill) transferrin20
ruling out that the bound species is the bare ruthenium(Ill) ion. Moreover, the fact that the CD
spectra of plus apoTf and II-plus apoTf, although similar, are different in shape and intensity
suggests that in the protein-bound species the heterocycle remains attached to the ruthenium(Ill)
ion.Vol. 3o No. 1, 1996 The Interaction ofthe Antitumor Complexes
Remarkably, the characteristic CD transitions are abolished by treating these adducts
with excess citrate (10 mM) at low pH (pH 4) indicating that the interaction of both
ruthenium(Ill) complexes with apoTf is reversible and acid labile.
Interaction with apoTf- 1HNMR spectra
Ruthenium(Ill) is paramagnetic_land is a reasonably .appropriate probe for 1H NMR
spectroscopy of paramagnetic species2 The paramagnetic 1H NMR spectra of and II are
characterized by a few, relatively narrow hyperfine signals spread within the upfield region. The
spectra are shown in Figure 4A and 4B. The assignment of the 1H NMR spectrum of has been
previously reported17. The spectrum of II is poorer and yet not assigned (Figure 4A and B); it is
straightfonNard, however, to attribute the intense (and virtually only) feature observed at-14 ppm
to the methyl groups of the ruthenium(lll)-bound DMSO moiety.
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Figure 4 1H NMR spectra of (a) and II (b) freshly dissolved in D20.
Conditions: 10 mM or II;T=25C.
Given the presence of these characteristic hyperfine signals in the respective spectra, we thought
that 1H NMR spectroscopy might represent a valuable technique to better characterize the
interaction of our ruthenium(Ill) complexes with diamagnetic apoTf.
a) I plus apoTf
The 200 MHz 1H NMR spectra of apoTf at increasing time intervals after addition of 2
equivalents of I, at 25 C, are shown in Figure 5. The spectra, all recorded within 4 hours after
mixing, cleady show that the signals of the free complex, and in particular the intense signal of
DMSO at-14 ppm, quickly disappear with time. Simultaneously, new hyperfine signals appear
both upfield and downfield, -signals labeled with an asterisk in figure 5-. This behavior suggests
that the odginal complex breaks down rapidly and its hydrolysis products bind the protein. The
new signals should correspond to those of the adduct of apoTf with the hydrolysis product of I.
The final spectrum is stable for hours, and is markedly different from that obtained upon reaction
of apoTf with two equivalents of II (see below).
b) II plus apoTf
Similar 1H NMR studies were performed to monitor the interaction of II with apoTf. TheL. Messori, F. Kratz andE. Alessio Metal-BasedDrugs
II I.
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Figure 5 1H NMR spectra of apoTf plus two equivalents of at different times after mixing
in the deuterated physiological buffer. The spectra were respectively recorded at 15’ (a), 60’ (b),
120’ (c), 180’ (d), and 240’ (e) after mixing. Conditions 2 mM [I] in the deuterated buffer with ImM
apoTf. T=25C.
Figure 6 1H NMR spectra of 1 mM apoTf
in the deuterated physiological buffer alone (a),
and 30’ (b) and 12 hours (c) after addition of two
equivalents of II in the physiological buffer.
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spectra are shown in Figure 6. Upon addition of two equivalents of II to a solution containing
lmM apoTf an intense, broad hyperfine signal at-15 ppm is observed; within few hours the
spectrum transforms into another spectrum characterized by an intense sharper resonance at -14
ppm. This spectrum is markedly different from that of plus-apoTf, implying a somewhat
unequivalent structure for the two adducts.Vol. 3, No. 1, 1996 The Interaction ofthe Antitumor Complexes
Discussion.
Targeting ofantitumor complexes.
The concept of drug targeting may be of great help when dealing with drugs
characterized by a narrow therapeutic index. The main goal of drug targeting strategies is to
obtain a more favorable biodistdbution of a drug within the organism, thus reducing its systemic
toxicity. Even if the selectivity of transferdn conjugates owing to the large distribution of the
transferdn receptors in the organism9- may not be as high as that of monoclonal antibodies
conjugates, transferrin conjugates show a number of properties that make them suitable for drug
targeting experiments. Indeed, by using transferdn as carder, it is possible, in principle, to
achieve a preferential uptake of the drug by those tissues that exhibit a large demand of iron, in
other words by fast replicating tissues like cancer tissues. Previous reports on the use of
transferrin as a carder of cytostatic drugs or toxins are in the literature12-15. We have attempted
to apply this strategy to a series of ruthenium(Ill) complexes with a structure resemblant that of
cisplatin.
Binding of and II to apoTf.
The preliminary-and indispensable- step of this kind of studies is represented by the
preparation and characterization of stable adducts between the metal complexes and transferrin
and by the assessment of their acid lability16. We have reported here on the interaction of and
II with apotransferrin under physiological conditions, as monitored by spectroscopic methods. The
absorption spectroscopy studies allowed us to describe in detail the hydrolysis processes that
occur when the two ruthenium(Ill) complexes are exposed to a neutral environment. In the
absence of transferrin, both complexes roughly follow the same hydrolysis pathway comprising a
"fast phase" that reaches completion within about half an hour and a "slow phase" that takes
hours. When repeating the same reaction in the presence of apoTf significant variations are
observed dudng the "slow phase", ascdbed to a direct interaction of the hydrolysis products of
both complexes with the protein. Following these preliminary indications, we have demonstrated
the occurrence of a specific interaction of both ruthenium(Ill) compounds with apoTf by means of
CD spectroscopy. The CD spectra of the drag/protein adducts, obtained at a 2:1 stoichiometry,
are similar but not identical suggesting that the heterocycle remains attached to the ruthenium(Ill)
ion. Moreover, we have demonstrated that the obtained drag/protein adducts, like the analogous
adducts with ru-im and ru-ind16, may be broken down by acification and complexation by citrate;
this finding is of particular interest since in vivo transferrin enters a cytoplasmic low pH
compartment where the loaded drug may be released.
Further, independent information on the protein-binding process has been gained by 1H
NMR spectroscopy, monitoring the hyperfine signals of the ruthenium(Ill) ligancls. In the case of
it is apparent that the signals of the free complex rapiclff decrease in intensity after mixing and
that a new set of hyperfine signals appear, both upfield and downfield. Such behavior clearly
reflects the hydrolysis of the free complex in the p.hysiological buffer and the subsequent binding
of the hydrolyzed species to the apoprotein. The 1H NMR behavior of II is apparently different:
upon hydrolysis the intense signal, attributed to the methyl groups of ruthenium(lll)-bound DMSO
changes slightly in shape and position, suggesting that DMSO remains attached to ruthenium(Ill)
in the protein bound species.
Comparison with ru-im and ru-ind.
Upon comparing the reactivity patterns of and II with those of ru-im and ru-ind, one can
state that all these compounds roughly behave in a similar way in that all bind apotransferrin
tightly, probably around the metal binding region, with a 2:1 drug/protein stoichiometry. The
possibility of forming stable adducts with apotransferrin is promising in view of targeting
strategies to tumor tissue; remarkably, all these adducts can release the bound ruthenium(Ill)
species upon exposure to citrate in a slightly acidic environment, a circumstance which is metL. Messori, F. Kratz andE. Alessio Metal-BasedDrugs
also in vivo. Them are however some important, distinctive features between the two classes of
compounds, such as the different kinetics of hydrolysis and protein binding and the different
water solubility. The latter feature, in particular, renders the DMSO containing compounds
attractive for future clinical applications.
Concluding Remarks
In the frame of a larger project on specific targeting of antitumor metal complexes
exploiting transferdn as a carder we have investigated the interaction of two water-soluble
antitumor ruthenium(Ill) complexes, and II, with the apoprotein. Noticeably the protein binds at
least two equivalents of both complexes. The binding process has been characterized through a
host of spectroscopic techniques comprising absorption, CD and 1H NMR spectroscopies.
Protein binding takes place only when the complexes have undergone the first step of their
hydrolytic process. The resulting adducts are stable for several hours under physiological
conditions; addition of excess citrate at low pH causes detachment of the bound ruthenium(Ill)
species. Apparently these adducts display sufficient requirements as to be tested in vitro and in
vivo for antitumor activity.
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